Table 3.
Overall survival of operable lung cancer patients with different stage from 2011 to 2020.
| Year | Overall survival of stage I | Overall survival of stage II | Overall survival of stage III | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | 10-year | 1-year | 3-year | 5-year | 10-year | 1-year | 3-year | 5-year | 10-year | |
| 2011 | 91.0% | 83.5% | 77.8% | 59.2% | 91.7% | 78.6% | 61.1% | 50.1% | 87.7% | 62.2% | 50.9% | 30.1% |
| 2012 | 96.6% | 93.0% | 88.5% | 82.7% | 78.1% | 68.3% | 91.2% | 61.1% | 50.8% | |||
| 2013 | 96.8% | 87.4% | 79.1% | 94.2% | 83.4% | 78.2% | 87.8% | 54.8% | 48.5% | |||
| 2014 | 97.5% | 92.8% | 89.1% | 88.7% | 82.7% | 80.3% | 85.2% | 70.2% | 61.5% | |||
| 2015 | 98.2% | 95.7% | 92.9% | 95.1% | 91.3% | 87.4% | 89.2% | 74.8% | 60.3% | |||
| 2016 | 98.1% | 95.7% | 87.4% | 94.8% | 93.4% | 83.8% | 93.1% | 88.9% | 71.4% | |||
| 2017 | 98.5% | 92.9% | 99.4% | 91.8% | 98.5% | 93.0% | ||||||
| 2018 | 100% | 97.1% | 100% | 83.8% | 97.3% | 85.0% | ||||||
| 2019 | 100% | 100% | 98.7% | |||||||||
| 2020 | 100% | 96.3% | 100% | |||||||||
| Total | 98.8% | 94.0% | 87.6% | 95.9% | 87.6% | 79.9% | 93.5% | 79.9% | 59.9% | |||
| p-value | <0.001 | <0.001 | 0.001 | <0.001 | 0.028 | 0.078 | <0.001 | <0.001 | 0.090 | |||